IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
about
Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosisMechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cellsInsulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential.The contradictions of the insulin-like growth factor 1 receptor.Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis.Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases.Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.Genetic Modulation of Neurocognitive Function in Glioma PatientsSelective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta1 integrins.The B cell translocation gene (BTG) family in the rat ovary: hormonal induction, regulation, and impact on cell cycle kineticsAnticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer.IGF-IR in neuroprotection and brain tumors.Nuclear IRS-1 and cancerThe role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapyTransmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle.MiR200c targets IRS1 and suppresses prostate cancer cell growth.IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells.Mutual interaction and reciprocal down-regulation between c-met and insulin receptor substrate-1.Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination.Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence.A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.Regulation of Id2 gene expression by the insulin-like growth factor I receptor requires signaling by phosphatidylinositol 3-kinase.Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells.Is PTEN loss associated with clinical outcome measures in human prostate cancer?MiR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells.Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis.Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue.Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas.
P2860
Q24670558-D248D8AC-6408-4C6E-9A9F-0DC6037DE283Q28213888-7FD06D51-BC14-4700-9BE3-81C881E56CD8Q34103184-C3DDB051-A58F-43D4-AFA3-3137DD0CA8FFQ34103628-93E49709-C467-48E8-B34D-B8836B557332Q35221417-25363B9B-04F7-407C-BB0F-82ADCF30DCE7Q35588605-4E03771A-3FF8-4A16-87DF-D23138A4B205Q35628188-F2ABF08C-5D90-4871-8A0B-F50D790A3DA6Q35862672-D0578505-A83C-4BE0-AB9D-98FB07AF8706Q36322254-843FF348-9EC8-4424-AB2D-963E8249A624Q37281063-24CCB12C-4E48-4537-B6C8-C606E311ACDCQ37397413-982238E5-9688-4D9D-B0F9-2B7ED5E63DFCQ37409955-818F35CE-41C0-4F41-A68A-BC48CFDDB941Q37997745-B948DB4E-4E65-4753-AA7A-809536DDFE35Q38175044-603B28B0-351D-4F15-A14F-1B2E79CD7400Q38177688-633CA14E-E416-406E-9BAD-F71AE4986E1FQ38831458-4E1A0966-0D47-4839-8806-FFE7B6E92BF1Q38909442-0E8AA48C-A905-476A-BB5F-5759BAF3C6B0Q38927010-35395E7E-E222-4A3F-A693-E598B4C8014FQ39033443-DF8E2F93-F7CB-4F23-A1EC-63019A1C7203Q39688384-AF9B2506-0D42-44A7-A209-D7DBFF60B04EQ39940494-0ECE8A83-0480-4395-8D7C-1BE3744077E6Q40443957-66DB520B-0E6A-4F2D-8B99-A336C19C6FB4Q40608574-A0525916-3DF3-473B-9678-61F3DBA4B2F7Q40816834-7BBD526F-06A6-49AB-9E21-6AD5C80A8EC7Q41985108-956FFBD1-157F-4CE4-81DA-96875C09A8A6Q43249619-ED415CB6-3A51-4E2B-BE92-C26B7A75523DQ44117797-573164E7-6EB6-4E8C-A100-3151CE8648E7Q46891012-DB6FCA9E-2CC5-4CBA-985B-CC6F6918D9AAQ47813155-BF239D24-7D56-4761-ABA6-4141A3A72D71Q54378660-25EFA74D-749F-4D7F-A42F-4694E097D696Q54650111-A9EB631D-92BE-4B2D-8DB3-C5DECB945118Q55474277-A24EB90B-FD93-4E1A-ACBB-3820A5A7EBCE
P2860
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
@en
type
label
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
@en
prefLabel
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
@en
P2093
P2860
P356
P1433
P1476
IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation.
@en
P2093
A Morrione
F B Furnari
W K Cavenee
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203587
P407
P577
2000-05-01T00:00:00Z
P5875
P6179
1045386828